2. Search Result
Search Result
Results for "

CCK-A

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

2

Peptides

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-118194
    A-65186

    		Cholecystokinin Receptor Others
    A-65186 is a CCK-A receptor antagonist with the activity of inhibiting CCK8-induced amylase secretion. A-65186 has high binding affinity for pancreatic CCK-A receptors, is more than 500 times more selective for CCK-A receptors than for CCK-B receptors, and can inhibit CCK8-induced amylase secretion.
    A-65186
  • HY-P1096
    A71623

    		Cholecystokinin Receptor Metabolic Disease
    A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .
    A71623
  • HY-U00387
    CCK-A receptor inhibitor 1

    		Cholecystokinin Receptor Metabolic Disease Endocrinology
    CCK-A receptor inhibitor 1 is a cholecystokinin A (CCK-A) receptor inhibitor with a binging IC50 of 340 nM.
    CCK-A receptor inhibitor 1
  • HY-RS02074
    CCKAR Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CCKAR Human Pre-designed siRNA Set A contains three designed siRNAs for CCKAR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CCKAR Human Pre-designed siRNA Set A
    CCKAR Human Pre-designed siRNA Set A
  • HY-118665
    L-736380

    		Cholecystokinin Receptor Metabolic Disease
    L-736380 is a high affinity CCK-B (cholecystokinin B receptor) receptor antagonist, with IC50 values of 0.054 nM and 400 nM for CCK-B and CCK-A, respectively. L-736380 dose-dependently inhibits gastric acid secretion in anesthetized rats (ID50, 0.064 mg/kg) and ex vivo binding of [125I]CCK-8S in BKTO mice brain membranes (ED50, 1.7 mg/kg) .
    L-736380
  • HY-U00062
    Tarazepide

    		Cholecystokinin Receptor Metabolic Disease Endocrinology
    Tarazepide is a potent and specific CCK-A receptor antagonist.
    Tarazepide
  • HY-U00363
    CHEMBL333994

    FK-480

    		 Cholecystokinin Receptor Endocrinology
    CHEMBL333994 is a potent and orally effective Cholecystokinin A (CCK-A) antagonist, with an IC50 of 0.67 nM.
    CHEMBL333994
  • HY-111918
    A71378

    		Cholecystokinin Receptor Metabolic Disease
    A71378 is a selectivity CCK-A receptor agonist the IC50 values of 0.4 nM, 300 nM, and 1,200 nM for the pancreatic CCK-A, cortical CCK-B, and gastrin receptor, respectively. A71378 elicits pancreatic amylase secretion (EC50 = 0.16 nM) and ileal muscle contraction (EC50 = 3.7 nM) .
    A71378
  • HY-123182
    PD-140548

    		Cholecystokinin Receptor Neurological Disease
    PD-140548 is a selective cholecystokinin (CCKA) receptor antagonist. PD-140548 can be used in schizophrenia research .
    PD-140548
  • HY-123434
    PD-149164

    		Cholecystokinin Receptor Metabolic Disease Endocrinology
    PD-149164 is a potent agonist of cholecystokinin B (CCK-B) receptor, with IC50 values of 0.083 nM and 75 nM in binding assay to CCK-B and CCK-A .
    PD-149164
  • HY-A0261
    Pentagastrin
    1 Publications Verification

    ICI-50123

    		 Cholecystokinin Receptor Endocrinology Cancer
    Pentagastrin (ICI-50123) is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury . .
    Pentagastrin
  • HY-A0261A
    Pentagastrin meglumine

    ICI-50123 meglumine

    		 Cholecystokinin Receptor Endocrinology Cancer
    Pentagastrin (ICI-50123) meglumine is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin meglumine enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury . .
    Pentagastrin meglumine
  • HY-169065
    Antibacterial agent 241

    		Bacterial Infection
    Antibacterial agent 241 is a histidine kinase (HK) inhibitor, with IC50 values of 14 μM and 238 μM for CckA and PhoQ, respectively. Antibacterial agent 241 shows moderate antibacterial activity against E. coli DC2, Bacillus cereus, and Bacillus subtilis, with a MIC range of 12-74 μg/mL .
    Antibacterial agent 241
  • HY-103355
    YM022
    2 Publications Verification

    		 CCR Metabolic Disease
    YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .
    YM022
  • HY-119127
    TP-680

    		Cholecystokinin Receptor Metabolic Disease
    TP-680 is a cholecystokinin receptor antagonist. TP-680 binds 1510 times more strongly to rat pancreatic CCKA receptors (IC50=1.2 nM) than to rat brain CCKB receptors (IC50=1812.5 nM). TP-680 can be used in the study of gastrointestinal diseases .
    TP-680
  • HY-128878
    Dexloxiglumide

    		Cholecystokinin Receptor P-glycoprotein Metabolic Disease Endocrinology
    Dexloxiglumide is an orally active and selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide is the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). Dexloxiglumide exhibits moderate Caco-2 permeability that is polarized, concentration dependent, and pH dependent. Dexloxiglumide increases MRP1-substrate fluorescein uptake. Dexloxiglumide can be studied in research for gastrointestinal diseases and tumors .
    Dexloxiglumide
  • HY-129516
    A-70874

    		Cholecystokinin Receptor Metabolic Disease
    A-70874 is a tyrosine-free tetrapeptide analog of cholecystokinin (30-33) (CCK-4). A-70874 is an agonist that stimulates pancreatic amylase release and a partial agonist that stimulates pancreatic phosphoinositide decomposition. A-70874 has an IC50 of 4.9 nM for the guinea pig pancreatic CCK receptor. Cholecystokinin (CCK) receptors are divided into CCK-A (digestive tract) and CCK-B (brain). A-70874 has an affinity of 1.6 μM for the CCK-B/gastrin receptor .
    A-70874
  • HY-128878R
    Dexloxiglumide (Standard)

    		Cholecystokinin Receptor P-glycoprotein Metabolic Disease Endocrinology
    Dexloxiglumide (Standard) is the analytical standard of Dexloxiglumide. This product is intended for research and analytical applications. Dexloxiglumide is an orally active and selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide is the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). Dexloxiglumide exhibits moderate Caco-2 permeability that is polarized, concentration dependent, and pH dependent. Dexloxiglumide increases MRP1-substrate fluorescein uptake. Dexloxiglumide can be studied in research for gastrointestinal diseases and tumors .
    Dexloxiglumide (Standard)
  • HY-103354
    Proglumide sodium
    1 Publications Verification

    		 Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .
    Proglumide sodium
  • HY-103354R
    Proglumide sodium (Standard)

    		Reference Standards Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide (sodium) (Standard) is the analytical standard of Proglumide (sodium). This product is intended for research and analytical applications. Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .
    Proglumide sodium (Standard)
  • HY-103354A
    Proglumide hemicalcium

    		Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities .
    Proglumide hemicalcium
  • HY-B1330R
    Proglumide (Standard)

    		Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide (Standard) is the analytical standard of Proglumide. This product is intended for research and analytical applications. Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .
    Proglumide (Standard)
  • HY-B1330
    Proglumide
    1 Publications Verification

    		 Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .
    Proglumide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: